Data Reinforces BERG’s Commitment to Improving the Standard of Care for Cancer Patients by Combining Biology with Artificial Intelligence for Next-Generation Precision Medicine
BOSTON, MA, USA I June 5, 2016 I BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510 (IV) in advanced solid tumors and BPM 31543 for the prevention of chemotherapy-induced alopecia at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois.
“These Phase I findings that we are presenting at ASCO demonstrates BERG’s commitment to improving the standard of care for cancer patients by unlocking the true potential of precision medicine,” said Niven R. Narain, co-founder, president and chief executive officer of BERG. “The promising data from these two trials supports our ‘back-to-biology’ approach, which places the patient at the center of our research and development.”
Presentation details:
Both posters presentations will be held on Sunday, June 5, 2016, from 8:00 a.m. to 11:30 a.m. CDT (9:00 a.m. – 12:30 p.m. EDT) in South Hall A at McCormick Place.
Title: Phase I study of BPM 31510 (IV) in advanced solid tumors: Omics-based molecular correlation to outcome for patient stratification (Abstract #2250)
BERG will be presenting interim data from its ongoing Phase I study of BPM 31510 (IV) in advanced solid tumors, which demonstrates the promise of metabolically-driven therapy by reversing the Warburg phenotype in cancer. BPM 31510 (IV) is one of the first cancer drugs guided in development by artificial intelligence. BPM 31510 (IV) appears to reverse the compromised metabolism of cancer cells which normalizes the cancer microenvironment to induce cell death. BERG’s Interrogative Biology® platform was used in its BPM 31510 (IV) Phase I study to discover molecular markers identifying patients more likely to have clinical benefit to the treatment applying a precision medicine approach to the trial.
Title: Topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a Phase I safety study (Abstract #2564)
BERG will also release data from its Phase I trial for its topical calcitriol, BPM 31543 for the prevention of chemotherapy-induced alopecia. Many cancer patients that are treated by chemotherapy encounter hair loss or alopecia as a major side effect, which can lead to significant psychosocial and quality of life issues. BERG’s topical compound BPM 31543 was developed to reduce chemotherapy-induced alopecia, and the data presented from the Phase I safety study shows that the topical compound is safe and well tolerated by patients with initial signs of efficacy.
About BERG
BERG is a biopharmaceutical company with divisions that include Analytics, Pharma, Biosystems and Diagnostics. Its research focus seeks to understand how alterations in metabolism relate to disease onset. BERG has uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of preclinical assets in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with the use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, BERG is poised to realize its pursuit of a healthier tomorrow. For additional information, please visit www.berghealth.com.
About the BERG Interrogative Biology® Platform:
BERG’s application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The BERG Interrogative Biology® platform integrates molecular data directly from a patient with clinical and demographic information to map the patient’s disease state. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.
SOURCE: BERG
Post Views: 154
Data Reinforces BERG’s Commitment to Improving the Standard of Care for Cancer Patients by Combining Biology with Artificial Intelligence for Next-Generation Precision Medicine
BOSTON, MA, USA I June 5, 2016 I BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510 (IV) in advanced solid tumors and BPM 31543 for the prevention of chemotherapy-induced alopecia at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois.
“These Phase I findings that we are presenting at ASCO demonstrates BERG’s commitment to improving the standard of care for cancer patients by unlocking the true potential of precision medicine,” said Niven R. Narain, co-founder, president and chief executive officer of BERG. “The promising data from these two trials supports our ‘back-to-biology’ approach, which places the patient at the center of our research and development.”
Presentation details:
Both posters presentations will be held on Sunday, June 5, 2016, from 8:00 a.m. to 11:30 a.m. CDT (9:00 a.m. – 12:30 p.m. EDT) in South Hall A at McCormick Place.
Title: Phase I study of BPM 31510 (IV) in advanced solid tumors: Omics-based molecular correlation to outcome for patient stratification (Abstract #2250)
BERG will be presenting interim data from its ongoing Phase I study of BPM 31510 (IV) in advanced solid tumors, which demonstrates the promise of metabolically-driven therapy by reversing the Warburg phenotype in cancer. BPM 31510 (IV) is one of the first cancer drugs guided in development by artificial intelligence. BPM 31510 (IV) appears to reverse the compromised metabolism of cancer cells which normalizes the cancer microenvironment to induce cell death. BERG’s Interrogative Biology® platform was used in its BPM 31510 (IV) Phase I study to discover molecular markers identifying patients more likely to have clinical benefit to the treatment applying a precision medicine approach to the trial.
Title: Topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a Phase I safety study (Abstract #2564)
BERG will also release data from its Phase I trial for its topical calcitriol, BPM 31543 for the prevention of chemotherapy-induced alopecia. Many cancer patients that are treated by chemotherapy encounter hair loss or alopecia as a major side effect, which can lead to significant psychosocial and quality of life issues. BERG’s topical compound BPM 31543 was developed to reduce chemotherapy-induced alopecia, and the data presented from the Phase I safety study shows that the topical compound is safe and well tolerated by patients with initial signs of efficacy.
About BERG
BERG is a biopharmaceutical company with divisions that include Analytics, Pharma, Biosystems and Diagnostics. Its research focus seeks to understand how alterations in metabolism relate to disease onset. BERG has uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of preclinical assets in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with the use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, BERG is poised to realize its pursuit of a healthier tomorrow. For additional information, please visit www.berghealth.com.
About the BERG Interrogative Biology® Platform:
BERG’s application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The BERG Interrogative Biology® platform integrates molecular data directly from a patient with clinical and demographic information to map the patient’s disease state. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.
SOURCE: BERG
Post Views: 154
